培美曲塞联合顺铂与吉西他滨联合顺铂治疗晚期非鳞非小细胞肺癌的疗效研究

Curative Effect Study on Pemetrexed Combined with Cisplatin and Gemcitabine Combined with Cisplatin in Treatment of Advanced Non-Squamous Non-small Cell Lung Cancer

目的探讨和比较培美曲塞联合顺铂(PC)与吉西他滨联合顺铂(GC)治疗晚期非鳞非小细胞肺癌的疗效,为临床治疗提供参考。方法选取2014年1月至2015年1月我院收治的非鳞非小细胞肺癌患者40例作为研究对象,按随机数字表法分为PC组和GC组,各20例,PC组给予培美曲塞联合顺铂治疗,GC组给予吉西他滨联合顺铂治疗,比较两组患者临床疗效、不良反应情况及随访生存情况。结果 GC组患者总有效率为50.00%,PC组总有效率为65.00%,两组比较差异无统计学意义(P>0.05);PC组白细胞减少、血小板减少发生率均低于GC组,差异有统计学意义(P<0.05),GC组6个月、1年、2年生存率均明显高于PC组,差异有统计学意义(P<0.05)。结论 PC与GC治疗晚期非鳞非小细胞肺癌总有效率相当,但PC方案不良反应轻,且6个月、1年、2年生存率较高。

Objective To investigate and compare the curative effect of pemetrexed combined with cisplatin and gemcitabine combined with cisplatin in the treatment of advanced non-squamous non-small cell lung cancer to provide reference for clinical treat- ment. Methods 40 patients with Non-squamous non-small cell lung cancer treated in our hospital from January 2014 to January 2015were selected and randomly divided into PC group and GC group, each group with 20 cases. The patients in the PC group were treated with pemetrexed combined with cisplatin, while the patients in the GC group were given gemcitabine combined with cisplatin. The clinical efficacy, adverse reactions and survival rate during the follow-up of the two groups were compared. Results The total ef- fective rates of the GC group and the PC group were 30.00% and 35.00% respectively, with no statistically significant difference （ P 〉0. 05）. The incidence rates of leukopenia and thrombocytopenia of the PC group were lower than those of the GC group, with statistically significant difference （P〈0. 05）. The survival rates of the patients in the GC group within 6 months, I year and 2 years after the treatment were significantly higher than those in the PC group, and the differences were statistically significant （ P〈0. 05 ）. Condusion The total effective rates of the PC group and the GC group in the treatment of advanced uon-squamous non-small cell lung cancer are well-matched. However, the adverse reaction is lighter and the survival rates within 6 months, 1 year and 2 years after the treatment are higher in the PC group.